Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sean Tu

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
JAMA|July 28, 2023
Patents and Regulatory Exclusivities on GLP-1 Receptor AgonistsRasha Alhiary, Aaron S Kesselheim, Sarah Gabriele, et al.
JAMA|November 25, 2024
Differential Legal Protections for Biologics vs Small-Molecule Drugs in the USOlivier J Wouters, Matthew Vogel, William B Feldman, et al.
JAMA Health Forum|August 22, 2025
Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the USDongzhe Hong, S Sean Tu, Reed F Beall, et al.
JAMA Health Forum|January 2, 2026
Tertiary Patents on Drugs Approved by the FDATheodore W Teng, S Sean Tu, Helen Mooney, et al.
JAMA Internal Medicine|November 28, 2022
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare SavingsAlexander C Egilman, Victor L Van de Wiele, Benjamin N Rome, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
JAMA|July 28, 2023
Patents and Regulatory Exclusivities on GLP-1 Receptor AgonistsRasha Alhiary, Aaron S Kesselheim, Sarah Gabriele, et al.
JAMA|November 25, 2024
Differential Legal Protections for Biologics vs Small-Molecule Drugs in the USOlivier J Wouters, Matthew Vogel, William B Feldman, et al.
JAMA Health Forum|August 22, 2025
Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the USDongzhe Hong, S Sean Tu, Reed F Beall, et al.
JAMA Health Forum|January 2, 2026
Tertiary Patents on Drugs Approved by the FDATheodore W Teng, S Sean Tu, Helen Mooney, et al.
JAMA Internal Medicine|November 28, 2022
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare SavingsAlexander C Egilman, Victor L Van de Wiele, Benjamin N Rome, et al.
Pageof 6